Effectiveness of omega-3 supplementation in reducing the degree of steatotic liver disease associated with metabolic dysfunction in adults

<h2>Summary</h2><h3>Background</h3> Steatotic liver disease associated with metabolic dysfunction is the most common liver disease worldwide <b>.</b> Currently, there are no specific medications for its treatment, so it is necessary to seek options that contribute to slowing its progression and reversing it in its early stages <b>.</b> The objective The objective of this study was to determine the effectiveness of omega-3 supplementation in reducing the degree of steatotic liver disease associated with metabolic dysfunction in adults. <h3>Methods</h3> A quasi-experimental study with 40 participants aged 25 years and older was conducted from August 2024 to April 2025, in Trujillo, Peru. Data were collected through an interview and medical evaluation. An abdominal ultrasound was performed to confirm the diagnosis of liver disease, as well as blood transaminase tests, among others. Descriptive and inferential statistics were applied in the statistical analysis. The experimental group received omega-3 supplementation for two months; the control group was recommended a low-carbohydrate and low-fat diet. Both groups were evaluated with abdominal ultrasound at the third month. <h3>Results</h3> The relevant anthropometric parameters were abdominal obesity (95%) and overweight (55%). Statistical significance was found after supplementation (p = 0.005 < 0.05). <h3>Conclusions</h3> Omega-3 supplementation at a dose of 1000 mg every 12 hours for 2 months was effective in significantly reducing the degree of steatotic liver disease associated with metabolic dysfunction in adults, showing that it is possible to obtain a favorable effect in the short term and with a lower probability of adverse effects.